此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

AI-Assisted Management of Diabetes and Hypertension in Primary Care

2026年11月11日 更新者:Jiangsu Taizhou People's Hospital

Brief Summary:

Many older adults in rural areas suffer from both type 2 diabetes and high blood pressure. Managing these two conditions at the primary care level is often challenging. This study aims to find out if a new "village doctor-led digital management model" can help improve patient health compared to the current standard care.

Who can participate? Adults aged 60 or older who have been diagnosed with both type 2 diabetes and high blood pressure, whose current blood sugar or blood pressure is not well-controlled, and who receive care at local village clinics.

How does the study work?

Village clinics will be randomly assigned to one of two groups:

Usual Care Group: Patients receive standard national primary health services.

Integrated Care Group: In addition to standard care, village doctors will use an Artificial Intelligence (AI) system. This system provides clinical suggestions to the village doctors, helps arrange remote consultations with hospital specialists if needed, and gives patients personalized advice on diet and exercise.

What are we measuring? We will follow participants for up to 3 years. The main goals are to see if the new AI-assisted model improves the control of blood sugar, blood pressure, and cholesterol at 12 months, and whether it reduces the risk of severe cardiovascular events (like heart attacks or strokes) over 36 months.

研究概览

研究类型

介入性

注册 (估计的)

9245

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

60年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

IInclusion Criteria:

Age ≥ 60 years. Previously diagnosed with both type 2 diabetes mellitus and hypertension. Inadequate glycemic control (HbA1c ≥ 7.5%; or HbA1c ≥ 8.0% if accompanied by clinical cardiovascular disease) OR inadequate blood pressure control (systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg).

Signed a family doctor service agreement with the local village doctor. Agree to participate in the study and provide written informed consent.

Exclusion Criteria:

Severe physical or psychological problems. Unable to attend on-site visits. Unable to answer questions independently. Unable to reside in the participating community for more than 1 year. Life expectancy less than 3 years. Participated in any other clinical trial within the past 6 months.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Integrated Care Group

Village doctor-led integrated digital management, including LLM-assisted decision support, remote specialist collaboration, and individualized lifestyle intervention.

A digital platform that integrates patient data and uses a large language model to provide risk alerts and management suggestions to village doctors for review.

Village doctors can initiate remote consultations with specialists (e.g., endocrinology, cardiology) through the platform for complex or poorly controlled cases.

Usual care according to the National Basic Public Health Service requirements.

其他:Usual Care Group

Usual care according to the National Basic Public Health Service requirements.

Usual care according to the National Basic Public Health Service requirements.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Proportion of participants achieving at least 2 of 3 ABC goals at 12 months
大体时间:12 months post-randomization

The proportion of participants achieving at least two of the following three predefined goals at 12 months post-randomization: A (HbA1c control), B (Blood pressure control), and C (LDL-C control).

12 months post-randomization
Time to first Major Adverse Cardiovascular Event (MACE) within 36 months
大体时间:Up to 36 months post-randomization

The time from randomization to the first occurrence of a Major Adverse Cardiovascular Event (MACE) within 36 months.

Up to 36 months post-randomization

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月14日

初级完成 (估计的)

2029年11月14日

研究完成 (估计的)

2029年11月14日

研究注册日期

首次提交

2026年10月27日

首先提交符合 QC 标准的

2026年11月11日

首次发布 (实际的)

2026年11月17日

研究记录更新

最后更新发布 (实际的)

2026年11月17日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅